甲状腺髓样癌的手术范围与隐匿性对侧病灶的患病率
这项多机构回顾性队列研究纳入1998年9月至2022年4月接受甲状腺切除术且有术前影像的176例甲状腺髓样癌患者,评估术前超声未发现的对侧隐匿病灶。全队列中46例(26.0%)有对侧病灶,9例(5.1%)为超声隐匿性对侧病灶;散发性患者对侧病灶风险显著低于胚系RET变异者(OR 0.043)。作者认为散发性且对侧超声无异常者可考虑先行甲状腺腺叶切除。
要点
- 全队列176例中46例(26.0%)存在对侧病灶,9例(5.1%)为术前超声未发现的隐匿对侧病灶。
- 散发性患者对侧病灶风险显著低于胚系RET变异者,OR 0.043(95%CI 0.013-0.123)。
- 仅行腺叶切除且有术后降钙素结果者中,5/12(41.7%)降钙素降至不可测(<2.0 pg/mL)。
核心结论
- 作者认为,散发性甲状腺髓样癌且对侧超声无异常者,可考虑先行甲状腺腺叶切除的分期策略,若降钙素降至不可测则不再手术。
- 作者提出需进一步开展前瞻性随机临床试验,评估以腺叶切除作为单侧病变患者生化治愈手段的价值。
研究设计与样本
- 多机构回顾性队列研究,1998年9月至2022年4月在学术医疗中心开展,纳入接受甲状腺切除术且有术前影像的甲状腺髓样癌患者176例。
- 患者诊断时中位年龄55岁(范围2-87岁),其中女性69例(57.6%)。
- 109例(61.9%)接受基因检测,其中48例(27.5%)携带胚系RET变异。
- 初始手术方式为全甲状腺切除161例(91.0%)、腺叶切除后补行全甲状腺切除7例(4.0%)、仅行腺叶切除8例(4.5%);146例(83.1%)在初始治疗中行中央区和侧颈淋巴结清扫。
主要发现
- 全队列176例中46例(26.0%)存在对侧病灶,9例(5.1%)为术前超声未发现的对侧隐匿病灶。
- 接受基因检测的109例中38例(34.9%)存在对侧病灶,其中8例(7.3%)为术前超声未发现的对侧隐匿病灶。
- 散发性甲状腺髓样癌患者对侧腺叶存在髓样癌病灶的风险较胚系RET变异者降低95.7%(OR 0.043;95%CI 0.013-0.123)。
- 校正年龄、性别、肿瘤大小和淋巴结受累后,散发性患者存在对侧髓样癌的OR为0.034(95%CI 0.007-0.116)。
- 仅行腺叶切除且有术后降钙素结果的患者中,12例中5例(41.7%)降钙素降至不可测水平(<2.0 pg/mL;换算为pmol/L需乘以0.292)。
关键数值与推荐
- 全队列对侧病灶患病率26.0%(46/176),超声隐匿性对侧病灶患病率5.1%(9/176)。
临床怎么用
- 作者认为,散发性甲状腺髓样癌且对侧超声无异常者可考虑先行甲状腺腺叶切除的分期策略,若降钙素降至不可测则不再手术。
- 作者提出需进一步开展前瞻性随机临床试验,评估腺叶切除作为单侧病变患者生化治愈手段的价值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Standard treatment for patients with medullary thyroid cancer (MTC) consists of total thyroidectomy with central neck dissection, but the rationale for bilateral surgery in patients with unilateral disease on ultrasonography remains unclear. OBJECTIVE: To determine the presence of occult contralateral disease (lesions not seen on preoperative ultrasonography) in patients with MTC as a rationale for total thyroidectomy. DESIGN, SETTING, AND PARTICIPANTS: This multi-institutional, retrospective cohort study was conducted from September 1998 to April 2022 in academic medical centers and included patients with MTC who underwent thyroidectomy with preoperative imaging. MAIN OUTCOMES AND MEASURES: The primary end point was the prevalence of sonographically occult foci of MTC in the contralateral lobe among patients with sporadic MTC. RESULTS: The cohort comprised 176 patients with a median age at diagnosis of 55 years (range, 2-87 years), 69 (57.6%) of whom were female. Genetic testing was performed in 109 patients (61.9%), 48 (27.5%) of whom carried germline RET variants. Initial surgical management consisted of total thyroidectomy (161 [91.0%]), lobectomy followed by completion thyroidectomy (7 [4.0%]), and lobectomy alone (8 [4.5%]). Central and lateral neck dissections were performed as part of initial therapy for 146 patients (83.1%). In the entire cohort of 176 patients, 46 (26.0%) had contralateral foci disease and 9 (5.1%) had occult contralateral foci that were not identified on preoperative ultrasonography. Among 109 patients who underwent genetic testing, 38 (34.9%) had contralateral disease, 8 (7.3%) of whom had occult contralateral disease not seen on preoperative ultrasonography. Patients with sporadic MTC experienced a 95.7% reduction in the odds of having a focus of MTC in the contralateral lobe compared with patients with a germline RET variant (odds ratio, 0.043; 95% CI, 0.013-0.123). When adjusting for age, sex, tumor size, and lymph node involvement, the odds ratio of having contralateral MTC in patients with sporadic disease was 0.034 (95% CI, 0.007-0.116). Among patients who underwent lobectomy alone with postoperative calcitonin levels, 5 of 12 (41.7%) achieved undetectable calcitonin levels (<2.0 pg/mL; to convert to pmol/L, multiply by 0.292). CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that a staged approach involving initial thyroid lobectomy could be considered in patients with sporadic MTC and no contralateral ultrasonography findings, with no further surgery if calcitonin levels became undetectable. Further work using prospective randomized clinical trials to evaluate lobectomy as a biochemical cure in patients presenting with unilateral disease is warranted.
引用
- Mao YV, Hughes EG, Steinmetz D, et al. Extent of Surgery for Medullary Thyroid Cancer and Prevalence of Occult Contralateral Foci. JAMA Otolaryngol Head Neck Surg. 2024. PMID: 38270925. doi:10.1001/jamaoto.2023.4376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。